Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2024-05-08 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
美股公告：季度报告10-Q表格
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC), as indicated by the header and the explicit mention of "Form 10-Q" and the quarterly period ending March 31, 2024. It contains detailed unaudited financial statements including income statement, balance sheet, cash flow statement, and notes, as well as management discussion and analysis sections. The document is approximately 15,000 characters long, which is consistent with a full quarterly report rather than a brief announcement or certification. The presence of detailed financial data and analysis confirms it is a comprehensive interim report for a fiscal quarter. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2024
2024-05-08 Chinese
百济神州有限公司2024年第一季度主要财务数据公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as "2024年第一季度主要财务数据公告" which translates to "2024 First Quarter Major Financial Data Announcement." It contains detailed financial data for the first quarter of 2024, including revenue, profit, net income, and other financial metrics. The data is preliminary and unaudited, prepared according to Chinese accounting standards, and includes a detailed explanation of business performance and financial conditions. The document is over 6,000 characters, indicating it is a substantive report rather than a brief announcement. It explicitly states it is a quarterly financial data report and includes comprehensive financial figures and analysis for the quarter ending March 31, 2024. This matches the definition of an Interim / Quarterly Report (IR). It is not a mere announcement of a report, nor a certification or regulatory filing. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-05-08 Chinese
港股公告：百济神州有限公司截至2024年3月31日止三个月未经审核业绩以及业务进展最新情况
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of BeiGene, Ltd.'s unaudited financial results and business progress for the first quarter ending March 31, 2024. It includes comprehensive financial data such as revenue, operating expenses, net loss, earnings per share, and segment performance. The document references GAAP and non-GAAP financial measures, detailed pipeline updates, regulatory approvals, and business highlights. It also mentions the filing of the 10-Q quarterly report with the SEC, indicating this is a quarterly financial disclosure. The length of the document (over 10,000 characters) and the inclusion of substantive financial statements and analysis confirm it is a full financial report rather than a brief announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-05-08 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly securities movement report for a listed issuer, detailing changes in registered and issued shares, stock options, and confirmations related to share issuance compliance with Hong Kong Stock Exchange Listing Rules. It includes detailed tables of share capital changes, share option plans, and confirmations by the company's executive director. The document is titled as a monthly report on securities changes under Chapter 19B of the Listing Rules, indicating it is a regulatory filing related to share capital changes but not a full financial report or earnings release. It is not an announcement of a report publication but a substantive regulatory filing. The content fits best under the category of Share Issue/Capital Change (SHA) as it reports on share capital and share option movements.
2024-05-07 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance, dates, share counts, prices, and related notes. It also contains a formal confirmation by the company's executive director and CEO regarding the authorization and compliance of the share issuance. The document length is 4014 characters, which is relatively short but contains substantive data on share capital changes, not merely an announcement of a report or a certification. This fits the category of a Transaction in Own Shares (POS) or Share Issue/Capital Change (SHA). Since the document details issuance of shares under share award plans and share option exercises, it is primarily about share capital changes rather than share repurchases. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2024-05-05 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A). It details share issuance under a share award plan, share counts before and after issuance, share prices, and related compliance confirmations. The document is structured as a regulatory disclosure of share capital changes, not a full financial report or announcement of a meeting or voting results. It is not an annual or interim report, earnings release, or management discussion. It is a formal regulatory filing specifically about share capital changes and share issuance disclosures. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is under 5,000 characters, but it contains detailed data on share issuance and changes, not just an announcement of a report publication, so it is not RPA or RNS. Confidence is high due to clear references to share issuance, share capital changes, and compliance with listing rules on share capital disclosures.
2024-04-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.